HU 012

Drug Profile

HU 012

Alternative Names: HU012

Latest Information Update: 19 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Huons
  • Class Antihyperlipidaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hyperlipidaemia

Most Recent Events

  • 17 Dec 2015 No development reported - Preclinical for Hyperlipidaemia in South Korea (unspecified route)
  • 31 Dec 2011 Preclinical trials in Hyperlipidaemia in South Korea (unspecified route) (Huons' pipeline, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top